Importer of Controlled Substances; Notice of Registration, 69589 [E6-20337]
Download as PDF
<![CDATA[
69589
rmajette on PROD1PC67 with NOTICES1
Federal Register / Vol. 71, No. 231 / Friday, December 1, 2006 / Notices
parties provide such information in
their hearing testimony and pre- and
posthearing briefs and other
submissions, to the extent they can.
Statements and Briefs: In lieu of or in
addition to participating in the hearing,
interested parties are invited to submit
written statements or briefs concerning
this investigation in accordance with
the requirements in the ‘‘Submissions’’
section below. Any pre-hearing briefs or
statements should be filed not later than
5:15 p.m., April 10, 2007; the deadline
for filing post-hearing briefs or
statements is 5:15 p.m., May 2, 2007.
Submissions: All written submissions,
including requests to appear at the
hearing, statements, and briefs, should
be addressed to the Secretary, United
States International Trade Commission,
500 E Street, SW., Washington, DC
20436. All written submissions must
conform with the provisions of section
201.8 of the Commission’s Rules of
Practice and Procedure (19 CFR 201.8);
any submission that contains
confidential business information must
also conform with the requirements of
section 201.6 of the Commission’s Rules
of Practice and Procedure (19 CFR
201.6). Section 201.8 of the rules require
that a signed original (or a copy
designated as an original) and fourteen
(14) copies of each document be filed.
In the event that confidential treatment
of the document is requested, at least
four (4) additional copies must be filed,
in which the confidential information
must be deleted. Section 201.6 of the
rules requires that the cover of the
document and the individual pages be
clearly marked as to whether they are
the ‘‘confidential’’ or ‘‘nonconfidential’’
version, and that the confidential
business information be clearly
identified by means of brackets. All
written submissions, except for
confidential business information, will
be made available for inspection by
interested parties.
In its request letter, the Committee
stated that it intends to make the
Commission’s report available to the
public in its entirety, and asked that the
Commission not include any
confidential business or national
security confidential information in the
report it sends to the Committee. The
report that the Commission sends to the
Committee will not contain any such
information. Any confidential business
information received by the
Commission in this investigation and
used in preparing the report will not be
published in a manner that would
reveal the operations of the firm
supplying the information.
Persons with mobility impairments
who will need special assistance in
VerDate Aug<31>2005
13:50 Nov 30, 2006
Jkt 211001
gaining access to the Commission
should contact the Secretary at 202–
205–2000.
By order of the Commission.
Issued: November 28, 2006.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E6–20374 Filed 11–30–06; 8:45 am]
BILLING CODE 7020–02–P
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20337 Filed 11–30–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated August 15, 2006 and
published in the Federal Register on
August 22, 2006, (71 FR 48946–48947),
Almac Clinical Services Incorporated
(ACSI) formerly known as Clinical Trial
Services, 2661 Audubon Road,
Audubon, Pennsylvania 19403, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
Schedule
Oxycodone (9143) ........................
Fentanyl (9801) ............................
II
II
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a)
and determined that the registration of
Almac Clinical Services Incorporation
(ACSI) to import the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Almac Clinical Services
Incorporation (ACSI) to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 25, 2006,
Chattem Chemicals, Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedule I and II:
Drug
N–Ethylamphetamine (1475)
2,5–Dimethoxyamphetamine
(7396).
4–Methoxyamphetamine
(7411).
Difenoxin (9168) .....................
Dihydromorphine (9145) ........
Amphetamine (1100) .............
Methamphetamine (1105) ......
Methylphenidate (1724) .........
Pentobarbital (2270) ..............
Secobarbital (2315) ................
Codeine (9050) ......................
Dihydrocodeine (9120) ...........
Oxycodone (9143) .................
Hydromorphone (9150) ..........
Diphenoxylate (9170) .............
Hydrocodone (9193) ..............
Meperidine (9230) ..................
Dextropropoxyphene, bulk
(non-dosage forms) (9273).
Morphine (9300) .....................
Thebaine (9333) .....................
Opium Extracts (9610) ...........
Opium Fluid Extract (9620) ....
Opium Tincture (9630) ...........
Opium, Granulated (9640) .....
Oxymorphone (9652) .............
Noroxymorphone (9668) ........
Opium, Powdered (9639) .......
Alfentanil (9737) .....................
Sufentanil (9740) ....................
Fentanyl (9801) ......................
Schedule
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR § 1301.33(a).
E:\FR\FM\01DEN1.SGM
01DEN1
]]>Agencies
[Federal Register Volume 71, Number 231 (Friday, December 1, 2006)]
[Notices]
[Page 69589]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20337]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated August 15, 2006 and published in the Federal
Register on August 22, 2006, (71 FR 48946-48947), Almac Clinical
Services Incorporated (ACSI) formerly known as Clinical Trial Services,
2661 Audubon Road, Audubon, Pennsylvania 19403, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as an importer of the basic classes of controlled substances listed in
schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Oxycodone (9143)........................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances in dosage form to conduct clinical trials.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and Sec. 952(a) and determined that
the registration of Almac Clinical Services Incorporation (ACSI) to
import the basic classes of controlled substances is consistent with
the public interest and with United States obligations under
international treaties, conventions, or protocols in effect on May 1,
1971, at this time. DEA has investigated Almac Clinical Services
Incorporation (ACSI) to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34,
the above named company is granted registration as an importer of the
basic classes of controlled substances listed.
Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-20337 Filed 11-30-06; 8:45 am]
BILLING CODE 4410-09-P
